{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:27:35Z","timestamp":1792013255128,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006383","name":"Cancer Society of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003756","name":"Biomedicum Helsinki Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008723","name":"Finnish Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008723","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Special State Funding of Medical Research"},{"name":"Eemil Aaltonen Foundation"},{"name":"Finnish-Norwegian Medical Fund"},{"name":"Finnish Gynaecological Society"},{"DOI":"10.13039\/100010125","name":"Jalmari and Rauha Ahokas Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010125","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ygyno.2019.05.024","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T08:13:36Z","timestamp":1559722416000},"page":"354-359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3467-7194","authenticated-orcid":false,"given":"Karoliina","family":"Aro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Nieminen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Louvanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"Jakobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seppo","family":"Virtanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Lehtinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Dillner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Kalliala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.05.024_bb0005","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","article-title":"Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis","volume":"7","author":"de Sanjos\u00e9","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0010","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0015","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"FUTURE II Study Group","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0020","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2019.05.024_bb0025","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0030","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0035","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0040","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years","volume":"199","author":"Brown","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0045","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","article-title":"Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica","volume":"1","author":"Herrero","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0050","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/ijc.31618","article-title":"Gender-neutral vaccination provides improved control of human papillomavirus types 18\/31\/33\/35 through herd immunity: results of a community randomized trial (III)","volume":"143","author":"Lehtinen","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.05.024_bb0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/infdis\/jix582","article-title":"Bivalent vaccine effectiveness against type-specific HPV positivity: evidence for cross-protection against oncogenic types among Dutch STI clinic visitors","volume":"217","author":"Woestenberg","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"CD009069","key":"10.1016\/j.ygyno.2019.05.024_bb0060","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0065","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrclinonc.2013.84","article-title":"Clinical trials of human papillomavirus vaccines and beyond","volume":"10","author":"Lehtinen","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0070","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/ijc.31231","article-title":"Vaccination protects against invasive HPV-associated cancers","volume":"142","author":"Luostarinen","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.05.024_bb0075","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3201\/eid2201.150736","article-title":"Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009\u20132013","volume":"22","author":"Cameron","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0080","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(17)30468-1","article-title":"Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study","volume":"17","author":"Kavanagh","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0085","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study","volume":"14","author":"Tabrizi","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0090","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1016\/j.vaccine.2018.04.080","article-title":"Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program","volume":"36","author":"Garland","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.ygyno.2019.05.024_bb0095","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1093\/infdis\/jiy075","article-title":"Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old Australian women 9 years following implementation of vaccination","volume":"217","author":"Machalek","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-015867","article-title":"Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials","volume":"7","author":"Lehtinen","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.ygyno.2019.05.024_bb0105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/cid\/cix797","article-title":"A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries","volume":"66","author":"Kjaer","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0110","doi-asserted-by":"crossref","first-page":"l1161","DOI":"10.1136\/bmj.l1161","article-title":"Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study","volume":"365","author":"Palmer","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ygyno.2019.05.024_bb0115","unstructured":"Finnish Cancer Registry. Cancer statistics (Finnish Cancer Registry) n.d. https:\/\/syoparekisteri.fi\/tilastot\/tautitilastot\/ (accessed August 21, 2018)."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0120","author":"Engholm"},{"key":"10.1016\/j.ygyno.2019.05.024_bb0125","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn510","article-title":"Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States","volume":"101","author":"Wheeler","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0130","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1055-9965.EPI-13-0053","article-title":"Age-specific occurrence of HPV16- and HPV18-related cervical cancer","volume":"22","author":"de Sanjose","year":"2013","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0135","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1158\/1055-9965.EPI-10-0131","article-title":"Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy","volume":"19","author":"Carozzi","year":"2010","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0140","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/ijc.30871","article-title":"Looking beyond human papillomavirus (HPV) genotype 16 and 18: defining HPV genotype distribution in cervical cancers in Australia prior to vaccination","volume":"141","author":"Brotherton","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.05.024_bb0145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jcv.2014.04.009","article-title":"Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence","volume":"60","author":"Carozzi","year":"2014","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0150","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa073204","article-title":"Human papillomavirus and Papanicolaou tests to screen for cervical cancer","volume":"357","author":"Naucler","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0155","doi-asserted-by":"crossref","first-page":"a1754","DOI":"10.1136\/bmj.a1754","article-title":"Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study","volume":"337","author":"Dillner","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ygyno.2019.05.024_bb0160","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ygyno.2019.05.024_bb0165","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1470-2045(11)70188-7","article-title":"Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study","volume":"12","author":"Castle","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0170","series-title":"Cytological Changes in the Cervix, Vagina and Vulva (Online)","volume":"vol. 2016","author":"Group set up by the Finnish Medical Society Duodecim W, the Finnish Colposcopy Association","year":"2016"},{"key":"10.1016\/j.ygyno.2019.05.024_bb0175","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/JCM.02007-08","article-title":"Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus","volume":"47","author":"S\u00f6derlund-Strand","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0180","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1086\/428779","article-title":"A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica","volume":"191","author":"Castle","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0185","series-title":"Working Group Set by National Institute for Health and Welfare (THL). Papilloomavirustautien torjuntaty\u00f6ryhm\u00e4n selvitys","year":"2011"},{"key":"10.1016\/j.ygyno.2019.05.024_bb0190","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1016\/j.vaccine.2008.05.064","article-title":"Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia","volume":"26","author":"Bosch","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ygyno.2019.05.024_bb0195","article-title":"Long-term antibody response to human papillomavirus vaccines: up to 12 years of follow-up in the Finnish maternity cohort","author":"Artemchuk","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0200","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1309\/AJCPZ5JY6FCVNMOT","article-title":"High-risk human papillomavirus testing in women with ASC-US cytology","volume":"135","author":"Stoler","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002666","article-title":"High-risk human papillomavirus status and prognosis in invasive cervical cancer: a nationwide cohort study","volume":"15","author":"Lei","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.ygyno.2019.05.024_bb0210","unstructured":"Cervixcancerprevention: Nationellt v\u00e5rdprogram och konsekvenser av inf\u00f6rande av Socialstyrelsens rekommendationer g\u00e4llande screening juni 2015 n.d. https:\/\/www.cancercentrum.se\/globalassets\/vara-uppdrag\/prevention-tidig-upptackt\/gynekologisk-cellprovskontroll\/vardprogram\/nvp-cervixcancerprevention-170119.pdf%0A (accessed December 14, 2018)."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819312685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819312685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:46:56Z","timestamp":1758772016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819312685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0090825819312685"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.05.024","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}